In connection with Royal Assent of the Pharmacare Act, we previously reported that the Minister of Health intended to negotiate bilateral agreements with provinces and territories to provide universal, single-payer, first-dollar access to a range of contraceptives and diabetes medications.
The Minister of Health recently announced the first of these bilateral agreements with Manitoba ($219 million over four years), British Columbia ($670 million over four years) and Prince Edward Island ($30 million over 4 years). Under the agreements, Manitoba and British Columbia will also provide free public coverage for hormone replacement therapy. Coverage is expected to begin in May 2025 (Prince Edward Island), June 2025 (Manitoba) and March 2026 (British Columbia).
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
2024 highlights in Canadian life sciences IP and regulatory law
In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
New PMPRB Draft Guidelines outline administrative process for excessive price hearing recommendations
On December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its Draft Guidelines for PMPRB Staff regarding Administrative Process for Excessive Price Hearing Recommendation (Draft...Read More -
Minister of Health announces new bilateral agreements with provinces for rare disease drugs
Canada’s first-ever National Strategy for Drugs for Rare Diseases includes up to $1.4 billion in funding for provinces and territories, to be negotiated through bilateral agreements.Read More